A 30-day survey of clinical trial notification to initiate a phase I/II study in Japan to evaluate ...

In Scientific Reports, the paper about the therapeutic efficacy of human adipocyte-derived platelet...

PRP business has been launched

Notice of Change in Management Structure and Head Office Relocation

Adopted in AMED's 2024 Project to Strengthen the Drug Discovery Venture Ecosystem

Mr. Hayakawa was appointed as our board director

Raised 1.6 billion yen through third-party allotment to prepare for clinical trials of ASCL-PLC

Concluded a basic agreement with H.U. Cells, Inc. regarding contracted business for PRP therapy

Notice of Management Change

Raised JPY 152 million through third-party allotment for the early commercialization of ASCL-PLC, a...

The disclosed information of the clinical study has been updated

AdipoSeeds raised 4 million JPY

AdipoSeeds received an acceptance about the compliance of the clinical study to the guideline for t...

The paper of ASCL-PLC was adopted as Plenary Paper of Blood

The patent of manufacturing platelets from adipose tissue-derived mesenchymal stem cell was registe...

AdipoSeeds became an affiliated institution for the research program funded by AMED